Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials.

MLA

Garg, Amit, et al. “Development and Initial Validation of the HS-IGA: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.” The British Journal of Dermatology, vol. 187, no. 2, Aug. 2022, pp. 203–10. EBSCOhost, https://doi.org/10.1111/bjd.21236.

APA

Garg, A., Zema, C., Kim, K., Gao, W., Chen, N., Jemec, G. B. E., Kirby, J., Thorlacius, L., Villumsen, B., & Ingram, J. R. (2022). Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials. The British Journal of Dermatology, 187(2), 203–210. https://doi.org/10.1111/bjd.21236

Chicago

Garg, Amit, Carla Zema, Katherine Kim, Weihua Gao, Naijun Chen, Gregor B E Jemec, Joslyn Kirby, Linnea Thorlacius, Bente Villumsen, and John R Ingram. 2022. “Development and Initial Validation of the HS-IGA: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.” The British Journal of Dermatology 187 (2): 203–10. doi:10.1111/bjd.21236.